Oportuzumab monatox

Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference

Thursday, April 8, 2021 - 1:55pm

He has appeared before the FDA as an expert including the presentation that led to the historic approval of BCG for NMIBC.

Key Points: 
  • He has appeared before the FDA as an expert including the presentation that led to the historic approval of BCG for NMIBC.
  • Dr. Jewett has published more than 400 peer-reviewed papers, mostly in Uro-oncology and in technology assessment and medical informatics.
  • In December 2020, Dr. Jewett was appointed to the Order of Canada based on his achievements listed above, among others.
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™

Monday, March 15, 2021 - 11:00am

The FDA also stated that they are not currently planning to hold an advisory committee meeting to discuss the BLA for Vicineum.

Key Points: 
  • The FDA also stated that they are not currently planning to hold an advisory committee meeting to discuss the BLA for Vicineum.
  • On March 5, 2021, Sesen Bio submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vicineum for the treatment of BCG-unresponsive NMIBC.
  • Under the Agreement, Qilu will be part of the contract manufacturing network for the global commercial supply of Vicineum.
  • Vicineum, a locally administered fusion protein, is Sesen Bios lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™

Monday, March 8, 2021 - 1:00pm

We will continue working collaboratively with the EMA to move Vicineum through the regulatory process as expeditiously as possible.

Key Points: 
  • We will continue working collaboratively with the EMA to move Vicineum through the regulatory process as expeditiously as possible.
  • Sesen Bio is currently going through the tradename approval process with the EMA for oportuzumab monatox.
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
  • Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company’s Lead Product Candidate Vicineum™

Tuesday, March 2, 2021 - 1:00pm

Neal Shore, M.D., FACS is the medical director of the Carolina Urologic Research Center and is an internationally recognized expert in Urologic Oncology.

Key Points: 
  • Neal Shore, M.D., FACS is the medical director of the Carolina Urologic Research Center and is an internationally recognized expert in Urologic Oncology.
  • Shore is a paid consultant to Sesen Bio and served as a clinical investigator for the Phase 2 and Phase 3 clinical trials of Vicineum for NMIBC.
  • Vicineum, a locally administered fusion protein, is Sesen Bios lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.